Team:Paris Bettencourt/Human Practice/Overview
From 2012.igem.org
(Difference between revisions)
Line 23: | Line 23: | ||
#:* '''''The need of a discussion''''' between society’s different protagonists to set goals, define what they would consider as benefits and acceptable risks (B), | #:* '''''The need of a discussion''''' between society’s different protagonists to set goals, define what they would consider as benefits and acceptable risks (B), | ||
# Best research practice: | # Best research practice: | ||
- | #:* ''''' | + | #:* Nowadays, a '''''risk 0 is impossible to achieve''''' as no containment system can be 100% safe (bacteria can always escape by mutations) (C), |
- | #:* ''''' | + | #:* There is a '''''lack of quantitative dataevaluating the probability of failure of containment systems''''' (D), |
- | #:* ''''' | + | #:* There is a '''''lack of quantitative data evaluating the risk of HGT assuming containment systems failed''''' (E), |
#:* The compiling of the wiki screen shows that '''''no containment systems created in iGEM is robust''''': they are all one mutation away from failure. We call for more biosafety in iGEM (F), | #:* The compiling of the wiki screen shows that '''''no containment systems created in iGEM is robust''''': they are all one mutation away from failure. We call for more biosafety in iGEM (F), | ||
#:* '''''The need for an INDEPENDENT committee of scientists''''' to test any application of synthetic biology that requires releasing in the environment (G), | #:* '''''The need for an INDEPENDENT committee of scientists''''' to test any application of synthetic biology that requires releasing in the environment (G), |
Revision as of 22:08, 26 September 2012
Human Practice
Aim To chart new venues of best practice for synthetic biology. To this end, we examined the ethical, biological and social concerns related to the release of genetically modified bacteria in the wild. Metodology
You can find the full list here Main Proposals
|